Rat and cynomolgus monkey (neither cross-reactive; target-independent toxicity only)
“The Applicant conducted repeat-dose toxicity studies of up to 6 months duration in rats and cynomolgus monkeys to investigate the chronic toxicity of inotuzumab ozogamicin;”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Why that species
No relevant species: G544 does not bind mouse, rat, rabbit or monkey B cells; tox limited to payload-driven, target-independent effects
“G544 did not bind B cells from mouse, rat, rabbit, or cynomolgus monkey whole blood, or granulocytes, MONO, or T cells from any species evaluated, including humans.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Surrogate molecule
No surrogate; clinical ADC in non-binding species, plus non-binding calicheamicin ADC (PF-06647259) investigative monkey study
“This study evaluated the target-independent toxicities of antibody-calicheamicin conjugates using a humanized nonbinding IgG1 monoclonal antibody conjugated to calicheamicin via the acid-labile AcBut linker (PF-06647259).”
✓ VerifiedFDA multi-discipline review, p. 53Source ↗